prikaz prve stranice dokumenta Stable Gastric Pentadecapeptide BPC 157 Heals Established Vesicovaginal Fistula and Counteracts Stone Formation in Rats
  Download
PDF 8.06 MB
Scientific paper - Original scientific paper
Stable Gastric Pentadecapeptide BPC 157 Heals Established Vesicovaginal Fistula and Counteracts Stone Formation in Rats
Biomedicines, 9 (2021), 9; 1206. https://doi.org/10.3390/biomedicines9091206
Rašić, Domagoj; Zenko Sever, Anita; Rašić, Fran; Štrbe, Sanja; Rašić, Žarko; Đuzel, Antonija; Duplančić, Božidar; Boban Blagaić, Alenka; Škrtić, Anita; Seiwerth, Sven; Sikirić, Predrag; Sever, Marko

Citations:
,

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Rašić, D., Zenko Sever, A., Rašić, F., Štrbe, S., Rašić, Ž., Đuzel, A. ... Sever, M. (2021). Stable Gastric Pentadecapeptide BPC 157 Heals Established Vesicovaginal Fistula and Counteracts Stone Formation in Rats. Biomedicines, 9. (9). doi: 10.3390/biomedicines9091206

Rašić, Domagoj, et al. "Stable Gastric Pentadecapeptide BPC 157 Heals Established Vesicovaginal Fistula and Counteracts Stone Formation in Rats." Biomedicines, vol. 9, no. 9, 2021. https://doi.org/10.3390/biomedicines9091206

Rašić, Domagoj, Anita Zenko Sever, Fran Rašić, Sanja Štrbe, Žarko Rašić, Antonija Đuzel, Božidar Duplančić, et al. "Stable Gastric Pentadecapeptide BPC 157 Heals Established Vesicovaginal Fistula and Counteracts Stone Formation in Rats." Biomedicines 9, no. 9 (2021). https://doi.org/10.3390/biomedicines9091206

Rašić, D., et al. (2021) 'Stable Gastric Pentadecapeptide BPC 157 Heals Established Vesicovaginal Fistula and Counteracts Stone Formation in Rats', Biomedicines, 9(9). doi: 10.3390/biomedicines9091206

Rašić D, Zenko Sever A, Rašić F, Štrbe S, Rašić Ž, Đuzel A, and sur.. Stable Gastric Pentadecapeptide BPC 157 Heals Established Vesicovaginal Fistula and Counteracts Stone Formation in Rats. Biomedicines [Internet]. 2021 September 13 [cited 2025 April 02];9(9). doi: 10.3390/biomedicines9091206

D. Rašić, et al., "Stable Gastric Pentadecapeptide BPC 157 Heals Established Vesicovaginal Fistula and Counteracts Stone Formation in Rats", Biomedicines, vol. 9, no. 9, September 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:928758. [Accessed: 02 April 2025]

Metadata
Title (english)Stable Gastric Pentadecapeptide BPC 157 Heals Established Vesicovaginal Fistula and Counteracts Stone Formation in Rats
AuthorDomagoj Rašić
AuthorAnita Zenko Sever
AuthorFran Rašić
AuthorSanja Štrbe
MBZ: 319335
AuthorŽarko Rašić
AuthorAntonija Đuzel
AuthorBožidar Duplančić
AuthorAlenka Boban Blagaić
AuthorAnita Škrtić
AuthorSven Seiwerth
AuthorPredrag Sikirić
AuthorMarko Sever
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Pharmacology)
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Pathology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Pharmacology
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Pathology
Abstract (english)
With the stable gastric pentadecapeptide BPC 157 therapy known to heal various both external and internal rat fistulas, we attempt to approach vesicovaginal fistula, continuous urine leaking through vagina, bladder stones, and a possible therapy solution among rats with well-formed 2 week-fistulas (vaginal/vesical 4 mm large defects) started with delayed therapy. Subsequent control fistula course (the subsequent 1, 2, 4, and 6 weeks) since beginning revealed the failed healing, fistula leaking,... More adhesions, urinary leaking through vagina, failed epithelization, collagenization, granulation tissue and neovascularization, increased inflammation, and necrosis. Thereby, the later intervals revealed the persistent inability to sustain even minimal volume, vesical, and vaginal defects and stone formation at the end of the experiment (fistula-time day 56). BPC 157 therapy (10 µg/kg, 10 ng/kg, intraperitoneally once time daily or perorally in drinking water until sacrifice) was initiated with a considerable delay (at 2 weeks after fistula formation). Already within 1 week therapy, all BPC 157 regimens stopped urinary leaking through vagina, reversed the otherwise resistant poor healing course to the increased epithelization, collagenization, granulation tissue and neovascularization, decreased inflammation, and decreased necrosis. Thereby, at later intervals, all BPC 157 rats exhibited a five times larger volume that can be sustained before leaking as in healthy, vesical, and vaginal defects completely closed and no stone formation. Thus, macro/microscopic and functional recovery, and counteracted stone formation. Concluding, BPC 157 therapy’s beneficial effects resulted in healing and no stone formation, with µg- and ng-regimens, either given daily perorally in drinking water or intraperitoneally. Less
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleBiomedicines
Numberingvol. 9, no. 9, 1206
e-ISSN2227-9059
DOIhttps://doi.org/10.3390/biomedicines9091206
URN:NBNurn:nbn:hr:105:928758
Publication2021-09-13
Document URLhttps://www.mdpi.com/2227-9059/9/9/1206
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2022-04-26 09:13:44
accessibility

closeAccessibilityrefresh

If you wish to permanently save changes, click on Save, if not - your settings will be reset when you restart the browser.